nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—Protein Kinase Inhibitors—Temsirolimus—kidney cancer	0.106	0.301	CiPCiCtD
Bosutinib—Vandetanib—Erlotinib—kidney cancer	0.102	0.635	CrCrCtD
Bosutinib—Protein Kinase Inhibitors—Sunitinib—kidney cancer	0.0806	0.228	CiPCiCtD
Bosutinib—SRMS—kidney cancer	0.0656	0.462	CbGaD
Bosutinib—Protein Kinase Inhibitors—Pazopanib—kidney cancer	0.0611	0.173	CiPCiCtD
Bosutinib—Protein Kinase Inhibitors—Everolimus—kidney cancer	0.0611	0.173	CiPCiCtD
Bosutinib—Gefitinib—Erlotinib—kidney cancer	0.0586	0.365	CrCrCtD
Bosutinib—P-Glycoprotein Inhibitors—Everolimus—kidney cancer	0.0441	0.125	CiPCiCtD
Bosutinib—LRRK2—kidney cancer	0.0423	0.297	CbGaD
Bosutinib—ALK—kidney cancer	0.0301	0.212	CbGaD
Bosutinib—STK36—Pazopanib—kidney cancer	0.00738	0.0321	CbGbCtD
Bosutinib—ULK3—Erlotinib—kidney cancer	0.00526	0.0229	CbGbCtD
Bosutinib—TAOK3—Pazopanib—kidney cancer	0.0049	0.0214	CbGbCtD
Bosutinib—PHKG1—Sunitinib—kidney cancer	0.0048	0.0209	CbGbCtD
Bosutinib—STK24—Sunitinib—kidney cancer	0.0048	0.0209	CbGbCtD
Bosutinib—CSNK1A1—Sunitinib—kidney cancer	0.0048	0.0209	CbGbCtD
Bosutinib—TNIK—Sunitinib—kidney cancer	0.0048	0.0209	CbGbCtD
Bosutinib—STK33—Sunitinib—kidney cancer	0.0048	0.0209	CbGbCtD
Bosutinib—CLK1—Sunitinib—kidney cancer	0.0048	0.0209	CbGbCtD
Bosutinib—MAP4K4—Sunitinib—kidney cancer	0.0048	0.0209	CbGbCtD
Bosutinib—MAP3K2—Pazopanib—kidney cancer	0.00424	0.0185	CbGbCtD
Bosutinib—ABCB1—kidney cancer	0.00411	0.0289	CbGaD
Bosutinib—LYN—Pazopanib—kidney cancer	0.00374	0.0163	CbGbCtD
Bosutinib—SLK—Erlotinib—kidney cancer	0.0035	0.0152	CbGbCtD
Bosutinib—ROCK1—Sunitinib—kidney cancer	0.00347	0.0151	CbGbCtD
Bosutinib—MAP2K1—Sunitinib—kidney cancer	0.00347	0.0151	CbGbCtD
Bosutinib—MAP3K12—Sunitinib—kidney cancer	0.00347	0.0151	CbGbCtD
Bosutinib—MAST1—Sunitinib—kidney cancer	0.00347	0.0151	CbGbCtD
Bosutinib—CSNK1E—Sunitinib—kidney cancer	0.00347	0.0151	CbGbCtD
Bosutinib—MAP2K2—Sunitinib—kidney cancer	0.00347	0.0151	CbGbCtD
Bosutinib—STK3—Sunitinib—kidney cancer	0.00347	0.0151	CbGbCtD
Bosutinib—ULK3—Sunitinib—kidney cancer	0.00347	0.0151	CbGbCtD
Bosutinib—MERTK—Sunitinib—kidney cancer	0.00347	0.0151	CbGbCtD
Bosutinib—RPS6KB1—Sunitinib—kidney cancer	0.00347	0.0151	CbGbCtD
Bosutinib—CAMK2G—Sunitinib—kidney cancer	0.00347	0.0151	CbGbCtD
Bosutinib—TBK1—Sunitinib—kidney cancer	0.00347	0.0151	CbGbCtD
Bosutinib—STK4—Sunitinib—kidney cancer	0.00347	0.0151	CbGbCtD
Bosutinib—MAP4K2—Sunitinib—kidney cancer	0.00347	0.0151	CbGbCtD
Bosutinib—LRRK2—Sunitinib—kidney cancer	0.00347	0.0151	CbGbCtD
Bosutinib—LOC400927-CSNK1E—Sunitinib—kidney cancer	0.00347	0.0151	CbGbCtD
Bosutinib—CHEK2—Sunitinib—kidney cancer	0.00347	0.0151	CbGbCtD
Bosutinib—MAP3K7—Sorafenib—kidney cancer	0.0034	0.0148	CbGbCtD
Bosutinib—STK10—Pazopanib—kidney cancer	0.00337	0.0147	CbGbCtD
Bosutinib—CSF1R—Pazopanib—kidney cancer	0.00337	0.0147	CbGbCtD
Bosutinib—MAP2K5—Pazopanib—kidney cancer	0.00306	0.0133	CbGbCtD
Bosutinib—PDGFRB—Pazopanib—kidney cancer	0.00306	0.0133	CbGbCtD
Bosutinib—LCK—Pazopanib—kidney cancer	0.00306	0.0133	CbGbCtD
Bosutinib—MAP3K19—Pazopanib—kidney cancer	0.00282	0.0123	CbGbCtD
Bosutinib—IRAK4—Sunitinib—kidney cancer	0.00275	0.012	CbGbCtD
Bosutinib—FYN—Sunitinib—kidney cancer	0.00275	0.012	CbGbCtD
Bosutinib—TYRO3—Sunitinib—kidney cancer	0.00275	0.012	CbGbCtD
Bosutinib—PTK2B—Sunitinib—kidney cancer	0.00275	0.012	CbGbCtD
Bosutinib—NUAK2—Sunitinib—kidney cancer	0.00275	0.012	CbGbCtD
Bosutinib—ALK—Sunitinib—kidney cancer	0.00275	0.012	CbGbCtD
Bosutinib—BMP2K—Sunitinib—kidney cancer	0.00275	0.012	CbGbCtD
Bosutinib—AXL—Sunitinib—kidney cancer	0.00275	0.012	CbGbCtD
Bosutinib—MAP4K1—Sunitinib—kidney cancer	0.00275	0.012	CbGbCtD
Bosutinib—MAP3K7—Sunitinib—kidney cancer	0.00275	0.012	CbGbCtD
Bosutinib—HIPK4—Erlotinib—kidney cancer	0.00267	0.0116	CbGbCtD
Bosutinib—STK10—Erlotinib—kidney cancer	0.0024	0.0105	CbGbCtD
Bosutinib—ABL2—Erlotinib—kidney cancer	0.0024	0.0105	CbGbCtD
Bosutinib—EGFR—Erlotinib—kidney cancer	0.0024	0.0105	CbGbCtD
Bosutinib—SLK—Sunitinib—kidney cancer	0.0023	0.01	CbGbCtD
Bosutinib—YES1—Sunitinib—kidney cancer	0.0023	0.01	CbGbCtD
Bosutinib—MAP4K5—Sunitinib—kidney cancer	0.0023	0.01	CbGbCtD
Bosutinib—MAP3K3—Sunitinib—kidney cancer	0.0023	0.01	CbGbCtD
Bosutinib—TAOK3—Sunitinib—kidney cancer	0.0023	0.01	CbGbCtD
Bosutinib—MAP2K5—Erlotinib—kidney cancer	0.00219	0.00952	CbGbCtD
Bosutinib—HIPK4—Sorafenib—kidney cancer	0.00217	0.00947	CbGbCtD
Bosutinib—MAP3K19—Erlotinib—kidney cancer	0.00201	0.00875	CbGbCtD
Bosutinib—IRAK1—Sunitinib—kidney cancer	0.00199	0.00868	CbGbCtD
Bosutinib—MAP3K2—Sunitinib—kidney cancer	0.00199	0.00868	CbGbCtD
Bosutinib—FGR—Sunitinib—kidney cancer	0.00199	0.00868	CbGbCtD
Bosutinib—STK10—Sorafenib—kidney cancer	0.00195	0.00851	CbGbCtD
Bosutinib—CSF1R—Sorafenib—kidney cancer	0.00195	0.00851	CbGbCtD
Bosutinib—MAP2K5—Sorafenib—kidney cancer	0.00178	0.00774	CbGbCtD
Bosutinib—PDGFRB—Sorafenib—kidney cancer	0.00178	0.00774	CbGbCtD
Bosutinib—BLK—Sunitinib—kidney cancer	0.00176	0.00767	CbGbCtD
Bosutinib—HIPK4—Sunitinib—kidney cancer	0.00176	0.00767	CbGbCtD
Bosutinib—ABL1—Erlotinib—kidney cancer	0.00174	0.00757	CbGbCtD
Bosutinib—MAP3K19—Sorafenib—kidney cancer	0.00163	0.00712	CbGbCtD
Bosutinib—CSF1R—Sunitinib—kidney cancer	0.00158	0.00689	CbGbCtD
Bosutinib—STK10—Sunitinib—kidney cancer	0.00158	0.00689	CbGbCtD
Bosutinib—STK10—renal vein—kidney cancer	0.00153	0.0625	CbGeAlD
Bosutinib—MAP2K5—Sunitinib—kidney cancer	0.00144	0.00627	CbGbCtD
Bosutinib—PDGFRB—Sunitinib—kidney cancer	0.00144	0.00627	CbGbCtD
Bosutinib—MAP3K19—Sunitinib—kidney cancer	0.00132	0.00577	CbGbCtD
Bosutinib—STK10—renal artery—kidney cancer	0.00103	0.042	CbGeAlD
Bosutinib—ABCB1—Temsirolimus—kidney cancer	0.000381	0.00166	CbGbCtD
Bosutinib—CYP3A4—Everolimus—kidney cancer	0.000338	0.00147	CbGbCtD
Bosutinib—Vandetanib—KDR—kidney cancer	0.000237	0.409	CrCbGaD
Bosutinib—CYP3A4—Temsirolimus—kidney cancer	0.000229	0.000996	CbGbCtD
Bosutinib—Vandetanib—VEGFA—kidney cancer	0.000201	0.347	CrCbGaD
Bosutinib—ABCB1—Pazopanib—kidney cancer	0.0002	0.000873	CbGbCtD
Bosutinib—TLK1—renal system—kidney cancer	0.000185	0.00756	CbGeAlD
Bosutinib—ABCB1—Dactinomycin—kidney cancer	0.000183	0.000799	CbGbCtD
Bosutinib—SIK2—renal system—kidney cancer	0.00018	0.00735	CbGeAlD
Bosutinib—VRK2—nephron tubule—kidney cancer	0.000177	0.00721	CbGeAlD
Bosutinib—FRK—renal system—kidney cancer	0.000176	0.00717	CbGeAlD
Bosutinib—TLK1—cortex of kidney—kidney cancer	0.000174	0.00712	CbGeAlD
Bosutinib—PRKCQ—cortex of kidney—kidney cancer	0.000172	0.00702	CbGeAlD
Bosutinib—CLK3—renal system—kidney cancer	0.000171	0.00699	CbGeAlD
Bosutinib—STK26—nephron tubule—kidney cancer	0.00017	0.00694	CbGeAlD
Bosutinib—TLK1—gonad—kidney cancer	0.000166	0.00678	CbGeAlD
Bosutinib—SRMS—renal system—kidney cancer	0.000164	0.00669	CbGeAlD
Bosutinib—WEE1—nephron tubule—kidney cancer	0.000163	0.00665	CbGeAlD
Bosutinib—STK33—gonad—kidney cancer	0.000162	0.00659	CbGeAlD
Bosutinib—CLK3—cortex of kidney—kidney cancer	0.000161	0.00659	CbGeAlD
Bosutinib—DSTYK—cortex of kidney—kidney cancer	0.000161	0.00659	CbGeAlD
Bosutinib—SRMS—kidney—kidney cancer	0.000159	0.00647	CbGeAlD
Bosutinib—SYK—renal system—kidney cancer	0.000158	0.00643	CbGeAlD
Bosutinib—PKMYT1—gonad—kidney cancer	0.000158	0.00643	CbGeAlD
Bosutinib—FRK—gonad—kidney cancer	0.000158	0.00643	CbGeAlD
Bosutinib—CDK2—renal system—kidney cancer	0.000156	0.00637	CbGeAlD
Bosutinib—EIF2AK1—cortex of kidney—kidney cancer	0.000156	0.00637	CbGeAlD
Bosutinib—STK25—nephron tubule—kidney cancer	0.000156	0.00635	CbGeAlD
Bosutinib—STK26—renal system—kidney cancer	0.000155	0.00631	CbGeAlD
Bosutinib—CLK3—gonad—kidney cancer	0.000154	0.00627	CbGeAlD
Bosutinib—CLK3—cardiac atrium—kidney cancer	0.000154	0.00626	CbGeAlD
Bosutinib—SYK—kidney—kidney cancer	0.000152	0.00621	CbGeAlD
Bosutinib—HIPK4—gonad—kidney cancer	0.000152	0.0062	CbGeAlD
Bosutinib—VRK2—cortex of kidney—kidney cancer	0.000151	0.00617	CbGeAlD
Bosutinib—CDK2—kidney—kidney cancer	0.000151	0.00616	CbGeAlD
Bosutinib—SIK3—nephron tubule—kidney cancer	0.00015	0.00613	CbGeAlD
Bosutinib—STK26—kidney—kidney cancer	0.00015	0.0061	CbGeAlD
Bosutinib—EIF2AK1—cardiac atrium—kidney cancer	0.000148	0.00606	CbGeAlD
Bosutinib—SYK—cortex of kidney—kidney cancer	0.000148	0.00605	CbGeAlD
Bosutinib—STK26—cortex of kidney—kidney cancer	0.000146	0.00594	CbGeAlD
Bosutinib—ABCB1—Gemcitabine—kidney cancer	0.000145	0.000631	CbGbCtD
Bosutinib—VRK2—cardiac atrium—kidney cancer	0.000144	0.00587	CbGeAlD
Bosutinib—ABCB1—Erlotinib—kidney cancer	0.000143	0.000623	CbGbCtD
Bosutinib—STK25—renal system—kidney cancer	0.000141	0.00577	CbGeAlD
Bosutinib—WEE1—cortex of kidney—kidney cancer	0.000139	0.00569	CbGeAlD
Bosutinib—DMPK—cortex of kidney—kidney cancer	0.000139	0.00569	CbGeAlD
Bosutinib—STK26—gonad—kidney cancer	0.000139	0.00566	CbGeAlD
Bosutinib—PLK2—renal system—kidney cancer	0.000138	0.00561	CbGeAlD
Bosutinib—STK25—cortex of kidney—kidney cancer	0.000133	0.00543	CbGeAlD
Bosutinib—PLK2—kidney—kidney cancer	0.000133	0.00542	CbGeAlD
Bosutinib—WEE1—gonad—kidney cancer	0.000133	0.00542	CbGeAlD
Bosutinib—WEE1—cardiac atrium—kidney cancer	0.000133	0.00541	CbGeAlD
Bosutinib—DMPK—cardiac atrium—kidney cancer	0.000133	0.00541	CbGeAlD
Bosutinib—ABCB1—Paclitaxel—kidney cancer	0.000131	0.00057	CbGbCtD
Bosutinib—PLK2—cortex of kidney—kidney cancer	0.000129	0.00528	CbGeAlD
Bosutinib—SIK3—cortex of kidney—kidney cancer	0.000129	0.00525	CbGeAlD
Bosutinib—STK25—gonad—kidney cancer	0.000127	0.00517	CbGeAlD
Bosutinib—STK25—cardiac atrium—kidney cancer	0.000127	0.00517	CbGeAlD
Bosutinib—PLK2—gonad—kidney cancer	0.000123	0.00503	CbGeAlD
Bosutinib—PLK2—cardiac atrium—kidney cancer	0.000123	0.00502	CbGeAlD
Bosutinib—SIK3—gonad—kidney cancer	0.000123	0.005	CbGeAlD
Bosutinib—SIK3—cardiac atrium—kidney cancer	0.000122	0.00499	CbGeAlD
Bosutinib—STK24—cortex of kidney—kidney cancer	0.000121	0.00493	CbGeAlD
Bosutinib—CYP3A4—Pazopanib—kidney cancer	0.00012	0.000523	CbGbCtD
Bosutinib—MAP4K4—nephron tubule—kidney cancer	0.000118	0.00481	CbGeAlD
Bosutinib—BCR—nephron tubule—kidney cancer	0.000117	0.00478	CbGeAlD
Bosutinib—NUAK2—nephron tubule—kidney cancer	0.000117	0.00478	CbGeAlD
Bosutinib—FER—cortex of kidney—kidney cancer	0.000117	0.00477	CbGeAlD
Bosutinib—CAMK1D—cardiac atrium—kidney cancer	0.000116	0.00475	CbGeAlD
Bosutinib—ABCB1—Sorafenib—kidney cancer	0.000116	0.000507	CbGbCtD
Bosutinib—ABCB1—Vinblastine—kidney cancer	0.000115	0.0005	CbGbCtD
Bosutinib—ROCK1—renal system—kidney cancer	0.000115	0.00468	CbGeAlD
Bosutinib—CSK—nephron tubule—kidney cancer	0.000113	0.00462	CbGeAlD
Bosutinib—ABCB1—Vincristine—kidney cancer	0.000113	0.000492	CbGbCtD
Bosutinib—CSNK1A1—nephron tubule—kidney cancer	0.000112	0.00459	CbGeAlD
Bosutinib—CLK1—nephron tubule—kidney cancer	0.000112	0.00456	CbGeAlD
Bosutinib—FER—gonad—kidney cancer	0.000111	0.00455	CbGeAlD
Bosutinib—TYRO3—gonad—kidney cancer	0.000111	0.00455	CbGeAlD
Bosutinib—BMPR2—renal system—kidney cancer	0.000111	0.00454	CbGeAlD
Bosutinib—FER—cardiac atrium—kidney cancer	0.000111	0.00454	CbGeAlD
Bosutinib—ROCK1—kidney—kidney cancer	0.000111	0.00452	CbGeAlD
Bosutinib—STK3—cortex of kidney—kidney cancer	0.000109	0.00446	CbGeAlD
Bosutinib—ERBB4—cortex of kidney—kidney cancer	0.000109	0.00446	CbGeAlD
Bosutinib—BMPR2—kidney—kidney cancer	0.000108	0.00439	CbGeAlD
Bosutinib—MAP4K4—renal system—kidney cancer	0.000107	0.00437	CbGeAlD
Bosutinib—BCR—renal system—kidney cancer	0.000106	0.00434	CbGeAlD
Bosutinib—BMPR2—cortex of kidney—kidney cancer	0.000105	0.00428	CbGeAlD
Bosutinib—ERBB4—cardiac atrium—kidney cancer	0.000104	0.00424	CbGeAlD
Bosutinib—STK36—cortex of kidney—kidney cancer	0.000104	0.00424	CbGeAlD
Bosutinib—MAP4K4—kidney—kidney cancer	0.000104	0.00423	CbGeAlD
Bosutinib—MAP2K1—renal system—kidney cancer	0.000104	0.00422	CbGeAlD
Bosutinib—CSK—renal system—kidney cancer	0.000103	0.0042	CbGeAlD
Bosutinib—ROCK1—gonad—kidney cancer	0.000103	0.00419	CbGeAlD
Bosutinib—SIK1—nephron tubule—kidney cancer	0.000103	0.00418	CbGeAlD
Bosutinib—CSNK1A1—renal system—kidney cancer	0.000102	0.00417	CbGeAlD
Bosutinib—CLK1—renal system—kidney cancer	0.000102	0.00414	CbGeAlD
Bosutinib—ERBB3—nephron tubule—kidney cancer	0.000101	0.0041	CbGeAlD
Bosutinib—NUAK2—cortex of kidney—kidney cancer	0.0001	0.00409	CbGeAlD
Bosutinib—BCR—cortex of kidney—kidney cancer	0.0001	0.00409	CbGeAlD
Bosutinib—MAP2K1—kidney—kidney cancer	0.0001	0.00408	CbGeAlD
Bosutinib—BMPR2—cardiac atrium—kidney cancer	9.97e-05	0.00407	CbGeAlD
Bosutinib—MAP3K2—nephron tubule—kidney cancer	9.96e-05	0.00406	CbGeAlD
Bosutinib—CSK—kidney—kidney cancer	9.94e-05	0.00406	CbGeAlD
Bosutinib—STK36—gonad—kidney cancer	9.91e-05	0.00404	CbGeAlD
Bosutinib—CSNK1A1—kidney—kidney cancer	9.88e-05	0.00403	CbGeAlD
Bosutinib—LRRK2—renal system—kidney cancer	9.88e-05	0.00403	CbGeAlD
Bosutinib—CLK1—kidney—kidney cancer	9.82e-05	0.004	CbGeAlD
Bosutinib—PTK2—nephron tubule—kidney cancer	9.75e-05	0.00398	CbGeAlD
Bosutinib—TBK1—nephron tubule—kidney cancer	9.75e-05	0.00398	CbGeAlD
Bosutinib—CSK—cortex of kidney—kidney cancer	9.68e-05	0.00395	CbGeAlD
Bosutinib—PTK2B—renal system—kidney cancer	9.63e-05	0.00393	CbGeAlD
Bosutinib—CASK—Temsirolimus—Everolimus—kidney cancer	9.62e-05	0.109	CbGdCrCtD
Bosutinib—CSNK1A1—cortex of kidney—kidney cancer	9.62e-05	0.00392	CbGeAlD
Bosutinib—MAP4K4—gonad—kidney cancer	9.61e-05	0.00392	CbGeAlD
Bosutinib—MAP4K4—cardiac atrium—kidney cancer	9.6e-05	0.00392	CbGeAlD
Bosutinib—CLK1—cortex of kidney—kidney cancer	9.56e-05	0.0039	CbGeAlD
Bosutinib—IRAK1—nephron tubule—kidney cancer	9.56e-05	0.0039	CbGeAlD
Bosutinib—LRRK2—kidney—kidney cancer	9.55e-05	0.0039	CbGeAlD
Bosutinib—BCR—gonad—kidney cancer	9.54e-05	0.00389	CbGeAlD
Bosutinib—BCR—cardiac atrium—kidney cancer	9.53e-05	0.00389	CbGeAlD
Bosutinib—MAP3K12—gonad—kidney cancer	9.48e-05	0.00387	CbGeAlD
Bosutinib—MAP3K12—cardiac atrium—kidney cancer	9.46e-05	0.00386	CbGeAlD
Bosutinib—ABCB1—Sunitinib—kidney cancer	9.42e-05	0.00041	CbGbCtD
Bosutinib—CAMK2G—cortex of kidney—kidney cancer	9.38e-05	0.00383	CbGeAlD
Bosutinib—SIK1—renal system—kidney cancer	9.32e-05	0.0038	CbGeAlD
Bosutinib—PTK2B—kidney—kidney cancer	9.31e-05	0.0038	CbGeAlD
Bosutinib—LRRK2—cortex of kidney—kidney cancer	9.3e-05	0.00379	CbGeAlD
Bosutinib—MAP2K1—gonad—kidney cancer	9.28e-05	0.00379	CbGeAlD
Bosutinib—STK35—gonad—kidney cancer	9.28e-05	0.00379	CbGeAlD
Bosutinib—STK35—cardiac atrium—kidney cancer	9.27e-05	0.00378	CbGeAlD
Bosutinib—CSK—gonad—kidney cancer	9.22e-05	0.00376	CbGeAlD
Bosutinib—Gefitinib—CYP1A1—kidney cancer	9.21e-05	0.159	CrCbGaD
Bosutinib—CSK—cardiac atrium—kidney cancer	9.21e-05	0.00376	CbGeAlD
Bosutinib—CSNK1A1—gonad—kidney cancer	9.16e-05	0.00374	CbGeAlD
Bosutinib—CSNK1A1—cardiac atrium—kidney cancer	9.15e-05	0.00373	CbGeAlD
Bosutinib—ERBB3—renal system—kidney cancer	9.14e-05	0.00373	CbGeAlD
Bosutinib—MAP2K2—renal system—kidney cancer	9.12e-05	0.00372	CbGeAlD
Bosutinib—CLK1—gonad—kidney cancer	9.1e-05	0.00371	CbGeAlD
Bosutinib—CLK1—cardiac atrium—kidney cancer	9.09e-05	0.00371	CbGeAlD
Bosutinib—SIK1—kidney—kidney cancer	9.01e-05	0.00368	CbGeAlD
Bosutinib—SLK—nephron tubule—kidney cancer	8.94e-05	0.00365	CbGeAlD
Bosutinib—BMP2K—gonad—kidney cancer	8.94e-05	0.00365	CbGeAlD
Bosutinib—CSNK1E—cortex of kidney—kidney cancer	8.92e-05	0.00364	CbGeAlD
Bosutinib—EPHB4—nephron tubule—kidney cancer	8.87e-05	0.00362	CbGeAlD
Bosutinib—TBK1—renal system—kidney cancer	8.86e-05	0.00362	CbGeAlD
Bosutinib—PTK2—renal system—kidney cancer	8.86e-05	0.00362	CbGeAlD
Bosutinib—LRRK2—gonad—kidney cancer	8.86e-05	0.00361	CbGeAlD
Bosutinib—ERBB3—kidney—kidney cancer	8.83e-05	0.0036	CbGeAlD
Bosutinib—MAP2K2—kidney—kidney cancer	8.81e-05	0.00359	CbGeAlD
Bosutinib—SIK1—cortex of kidney—kidney cancer	8.78e-05	0.00358	CbGeAlD
Bosutinib—CYP3A4—urine—kidney cancer	8.74e-05	0.00356	CbGeAlD
Bosutinib—CHEK2—Docetaxel—Paclitaxel—kidney cancer	8.72e-05	0.0992	CbGdCrCtD
Bosutinib—EPHA2—nephron tubule—kidney cancer	8.7e-05	0.00355	CbGeAlD
Bosutinib—FYN—nephron tubule—kidney cancer	8.69e-05	0.00354	CbGeAlD
Bosutinib—PTK2B—gonad—kidney cancer	8.63e-05	0.00352	CbGeAlD
Bosutinib—MAP2K2—cortex of kidney—kidney cancer	8.58e-05	0.0035	CbGeAlD
Bosutinib—ULK3—cortex of kidney—kidney cancer	8.58e-05	0.0035	CbGeAlD
Bosutinib—PTK2—kidney—kidney cancer	8.57e-05	0.0035	CbGeAlD
Bosutinib—TBK1—kidney—kidney cancer	8.57e-05	0.0035	CbGeAlD
Bosutinib—CYP3A4—Erlotinib—kidney cancer	8.57e-05	0.000373	CbGbCtD
Bosutinib—RPS6KB1—renal system—kidney cancer	8.53e-05	0.00348	CbGeAlD
Bosutinib—MAP3K3—nephron tubule—kidney cancer	8.49e-05	0.00346	CbGeAlD
Bosutinib—MAP3K7—cortex of kidney—kidney cancer	8.44e-05	0.00344	CbGeAlD
Bosutinib—SIK1—gonad—kidney cancer	8.36e-05	0.00341	CbGeAlD
Bosutinib—SIK1—cardiac atrium—kidney cancer	8.35e-05	0.00341	CbGeAlD
Bosutinib—TBK1—cortex of kidney—kidney cancer	8.34e-05	0.0034	CbGeAlD
Bosutinib—PTK2—cortex of kidney—kidney cancer	8.34e-05	0.0034	CbGeAlD
Bosutinib—EPHA4—gonad—kidney cancer	8.28e-05	0.00338	CbGeAlD
Bosutinib—EPHA4—cardiac atrium—kidney cancer	8.26e-05	0.00337	CbGeAlD
Bosutinib—RPS6KB1—kidney—kidney cancer	8.24e-05	0.00336	CbGeAlD
Bosutinib—IRAK1—cortex of kidney—kidney cancer	8.18e-05	0.00334	CbGeAlD
Bosutinib—ULK3—gonad—kidney cancer	8.17e-05	0.00333	CbGeAlD
Bosutinib—MAP2K2—gonad—kidney cancer	8.17e-05	0.00333	CbGeAlD
Bosutinib—ULK3—cardiac atrium—kidney cancer	8.16e-05	0.00333	CbGeAlD
Bosutinib—MAP2K2—cardiac atrium—kidney cancer	8.16e-05	0.00333	CbGeAlD
Bosutinib—MAP3K2—gonad—kidney cancer	8.12e-05	0.00331	CbGeAlD
Bosutinib—EPHB4—renal system—kidney cancer	8.07e-05	0.00329	CbGeAlD
Bosutinib—MAP3K7—cardiac atrium—kidney cancer	8.03e-05	0.00328	CbGeAlD
Bosutinib—RPS6KB1—cortex of kidney—kidney cancer	8.03e-05	0.00327	CbGeAlD
Bosutinib—TBK1—gonad—kidney cancer	7.95e-05	0.00324	CbGeAlD
Bosutinib—PTK2—gonad—kidney cancer	7.95e-05	0.00324	CbGeAlD
Bosutinib—AXL—cortex of kidney—kidney cancer	7.95e-05	0.00324	CbGeAlD
Bosutinib—TBK1—cardiac atrium—kidney cancer	7.94e-05	0.00324	CbGeAlD
Bosutinib—FYN—renal system—kidney cancer	7.9e-05	0.00322	CbGeAlD
Bosutinib—YES1—nephron tubule—kidney cancer	7.84e-05	0.0032	CbGeAlD
Bosutinib—CYP3A4—Paclitaxel—kidney cancer	7.84e-05	0.000342	CbGbCtD
Bosutinib—EPHB4—kidney—kidney cancer	7.8e-05	0.00318	CbGeAlD
Bosutinib—TAOK3—nephron tubule—kidney cancer	7.74e-05	0.00316	CbGeAlD
Bosutinib—SLK—cortex of kidney—kidney cancer	7.65e-05	0.00312	CbGeAlD
Bosutinib—FYN—kidney—kidney cancer	7.64e-05	0.00312	CbGeAlD
Bosutinib—RPS6KB1—cardiac atrium—kidney cancer	7.64e-05	0.00311	CbGeAlD
Bosutinib—EPHB4—cortex of kidney—kidney cancer	7.59e-05	0.0031	CbGeAlD
Bosutinib—AXL—gonad—kidney cancer	7.57e-05	0.00309	CbGeAlD
Bosutinib—AXL—cardiac atrium—kidney cancer	7.56e-05	0.00308	CbGeAlD
Bosutinib—FYN—cortex of kidney—kidney cancer	7.44e-05	0.00303	CbGeAlD
Bosutinib—SLK—cardiac atrium—kidney cancer	7.28e-05	0.00297	CbGeAlD
Bosutinib—MAP3K3—cortex of kidney—kidney cancer	7.27e-05	0.00296	CbGeAlD
Bosutinib—MAP4K5—cortex of kidney—kidney cancer	7.27e-05	0.00296	CbGeAlD
Bosutinib—EPHB4—cardiac atrium—kidney cancer	7.22e-05	0.00295	CbGeAlD
Bosutinib—YES1—renal system—kidney cancer	7.13e-05	0.00291	CbGeAlD
Bosutinib—EPHA2—cardiac atrium—kidney cancer	7.09e-05	0.00289	CbGeAlD
Bosutinib—FYN—cardiac atrium—kidney cancer	7.07e-05	0.00289	CbGeAlD
Bosutinib—STK10—renal system—kidney cancer	7.06e-05	0.00288	CbGeAlD
Bosutinib—ABCB1—Doxorubicin—kidney cancer	7.05e-05	0.000307	CbGbCtD
Bosutinib—TAOK3—renal system—kidney cancer	7.04e-05	0.00287	CbGeAlD
Bosutinib—CYP3A4—Sorafenib—kidney cancer	6.97e-05	0.000304	CbGbCtD
Bosutinib—MAP4K5—gonad—kidney cancer	6.92e-05	0.00282	CbGeAlD
Bosutinib—MAP3K3—gonad—kidney cancer	6.92e-05	0.00282	CbGeAlD
Bosutinib—MAP4K5—cardiac atrium—kidney cancer	6.91e-05	0.00282	CbGeAlD
Bosutinib—MAP3K3—cardiac atrium—kidney cancer	6.91e-05	0.00282	CbGeAlD
Bosutinib—YES1—kidney—kidney cancer	6.89e-05	0.00281	CbGeAlD
Bosutinib—CYP3A4—Vinblastine—kidney cancer	6.88e-05	0.0003	CbGbCtD
Bosutinib—SRC—renal system—kidney cancer	6.86e-05	0.0028	CbGeAlD
Bosutinib—STK10—kidney—kidney cancer	6.83e-05	0.00279	CbGeAlD
Bosutinib—TAOK3—kidney—kidney cancer	6.8e-05	0.00278	CbGeAlD
Bosutinib—CYP3A4—Vincristine—kidney cancer	6.76e-05	0.000295	CbGbCtD
Bosutinib—YES1—cortex of kidney—kidney cancer	6.71e-05	0.00274	CbGeAlD
Bosutinib—SRC—kidney—kidney cancer	6.63e-05	0.0027	CbGeAlD
Bosutinib—TAOK3—cortex of kidney—kidney cancer	6.63e-05	0.0027	CbGeAlD
Bosutinib—YES1—gonad—kidney cancer	6.39e-05	0.00261	CbGeAlD
Bosutinib—YES1—cardiac atrium—kidney cancer	6.38e-05	0.0026	CbGeAlD
Bosutinib—STK10—gonad—kidney cancer	6.34e-05	0.00258	CbGeAlD
Bosutinib—TAOK3—cardiac atrium—kidney cancer	6.3e-05	0.00257	CbGeAlD
Bosutinib—CDK2—Vinblastine—Vincristine—kidney cancer	6.27e-05	0.0713	CbGdCrCtD
Bosutinib—SRC—gonad—kidney cancer	6.15e-05	0.00251	CbGeAlD
Bosutinib—SRC—cardiac atrium—kidney cancer	6.14e-05	0.00251	CbGeAlD
Bosutinib—MAP2K5—cortex of kidney—kidney cancer	5.94e-05	0.00242	CbGeAlD
Bosutinib—CSK—Everolimus—Temsirolimus—kidney cancer	5.72e-05	0.0651	CbGdCrCtD
Bosutinib—CSK—Sirolimus—Everolimus—kidney cancer	5.72e-05	0.0651	CbGdCrCtD
Bosutinib—CSK—Sirolimus—Temsirolimus—kidney cancer	5.72e-05	0.0651	CbGdCrCtD
Bosutinib—CSK—Temsirolimus—Everolimus—kidney cancer	5.72e-05	0.0651	CbGdCrCtD
Bosutinib—MAP2K5—cardiac atrium—kidney cancer	5.65e-05	0.0023	CbGeAlD
Bosutinib—CYP3A4—Sunitinib—kidney cancer	5.64e-05	0.000246	CbGbCtD
Bosutinib—CSF1R—gonad—kidney cancer	5.52e-05	0.00225	CbGeAlD
Bosutinib—CSF1R—cardiac atrium—kidney cancer	5.51e-05	0.00225	CbGeAlD
Bosutinib—PDGFRB—renal system—kidney cancer	5.46e-05	0.00223	CbGeAlD
Bosutinib—WEE1—Daunorubicin—Doxorubicin—kidney cancer	5.39e-05	0.0614	CbGdCrCtD
Bosutinib—ABL1—nephron tubule—kidney cancer	5.35e-05	0.00218	CbGeAlD
Bosutinib—PDGFRB—kidney—kidney cancer	5.28e-05	0.00215	CbGeAlD
Bosutinib—PDGFRB—cortex of kidney—kidney cancer	5.14e-05	0.0021	CbGeAlD
Bosutinib—Gefitinib—ABCB1—kidney cancer	4.9e-05	0.0846	CrCbGaD
Bosutinib—PDGFRB—gonad—kidney cancer	4.9e-05	0.002	CbGeAlD
Bosutinib—PDGFRB—cardiac atrium—kidney cancer	4.89e-05	0.00199	CbGeAlD
Bosutinib—ABL1—renal system—kidney cancer	4.87e-05	0.00199	CbGeAlD
Bosutinib—ABL1—kidney—kidney cancer	4.71e-05	0.00192	CbGeAlD
Bosutinib—ABL1—cortex of kidney—kidney cancer	4.58e-05	0.00187	CbGeAlD
Bosutinib—CAMK2G—Azacitidine—Gemcitabine—kidney cancer	4.51e-05	0.0513	CbGdCrCtD
Bosutinib—CHEK2—Vindesine—Vinblastine—kidney cancer	4.43e-05	0.0504	CbGdCrCtD
Bosutinib—CHEK2—Vindesine—Vincristine—kidney cancer	4.43e-05	0.0504	CbGdCrCtD
Bosutinib—ABL1—gonad—kidney cancer	4.36e-05	0.00178	CbGeAlD
Bosutinib—ABL1—cardiac atrium—kidney cancer	4.36e-05	0.00178	CbGeAlD
Bosutinib—CYP3A4—Doxorubicin—kidney cancer	4.23e-05	0.000184	CbGbCtD
Bosutinib—ERBB3—Vinblastine—Vincristine—kidney cancer	2.85e-05	0.0324	CbGdCrCtD
Bosutinib—CHEK2—Vinorelbine—Vincristine—kidney cancer	2.8e-05	0.0318	CbGdCrCtD
Bosutinib—CHEK2—Vinorelbine—Vinblastine—kidney cancer	2.8e-05	0.0318	CbGdCrCtD
Bosutinib—CHEK2—Vincristine—Vinblastine—kidney cancer	2.39e-05	0.0272	CbGdCrCtD
Bosutinib—CYP3A4—renal system—kidney cancer	2.14e-05	0.000872	CbGeAlD
Bosutinib—Abdominal pain—Sorafenib—kidney cancer	2.12e-05	0.000525	CcSEcCtD
Bosutinib—Body temperature increased—Sorafenib—kidney cancer	2.12e-05	0.000525	CcSEcCtD
Bosutinib—Diarrhoea—Everolimus—kidney cancer	2.11e-05	0.000524	CcSEcCtD
Bosutinib—Gastrointestinal pain—Sunitinib—kidney cancer	2.11e-05	0.000523	CcSEcCtD
Bosutinib—Hepatobiliary disease—Capecitabine—kidney cancer	2.11e-05	0.000523	CcSEcCtD
Bosutinib—Pruritus—Erlotinib—kidney cancer	2.11e-05	0.000522	CcSEcCtD
Bosutinib—Fatigue—Dactinomycin—kidney cancer	2.11e-05	0.000522	CcSEcCtD
Bosutinib—Pain—Dactinomycin—kidney cancer	2.09e-05	0.000518	CcSEcCtD
Bosutinib—Agranulocytosis—Capecitabine—kidney cancer	2.08e-05	0.000516	CcSEcCtD
Bosutinib—Dysgeusia—Paclitaxel—kidney cancer	2.08e-05	0.000515	CcSEcCtD
Bosutinib—Anaphylactic shock—Gemcitabine—kidney cancer	2.07e-05	0.000513	CcSEcCtD
Bosutinib—Oedema—Gemcitabine—kidney cancer	2.07e-05	0.000513	CcSEcCtD
Bosutinib—CYP3A4—kidney—kidney cancer	2.07e-05	0.000843	CbGeAlD
Bosutinib—Infection—Gemcitabine—kidney cancer	2.06e-05	0.00051	CcSEcCtD
Bosutinib—Back pain—Paclitaxel—kidney cancer	2.06e-05	0.000509	CcSEcCtD
Bosutinib—Dizziness—Vinblastine—kidney cancer	2.05e-05	0.000508	CcSEcCtD
Bosutinib—Dizziness—Everolimus—kidney cancer	2.04e-05	0.000506	CcSEcCtD
Bosutinib—Abdominal pain—Sunitinib—kidney cancer	2.04e-05	0.000505	CcSEcCtD
Bosutinib—Body temperature increased—Sunitinib—kidney cancer	2.04e-05	0.000505	CcSEcCtD
Bosutinib—Diarrhoea—Erlotinib—kidney cancer	2.04e-05	0.000505	CcSEcCtD
Bosutinib—Nervous system disorder—Gemcitabine—kidney cancer	2.03e-05	0.000503	CcSEcCtD
Bosutinib—Thrombocytopenia—Gemcitabine—kidney cancer	2.03e-05	0.000502	CcSEcCtD
Bosutinib—Renal failure acute—Doxorubicin—kidney cancer	2.02e-05	0.000501	CcSEcCtD
Bosutinib—Feeling abnormal—Dactinomycin—kidney cancer	2.01e-05	0.000499	CcSEcCtD
Bosutinib—Skin disorder—Gemcitabine—kidney cancer	2.01e-05	0.000498	CcSEcCtD
Bosutinib—Hepatitis—Capecitabine—kidney cancer	2e-05	0.000496	CcSEcCtD
Bosutinib—Gastrointestinal pain—Dactinomycin—kidney cancer	2e-05	0.000495	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Vincristine—kidney cancer	1.99e-05	0.000493	CcSEcCtD
Bosutinib—Urinary tract disorder—Capecitabine—kidney cancer	1.98e-05	0.00049	CcSEcCtD
Bosutinib—Oedema peripheral—Capecitabine—kidney cancer	1.97e-05	0.000489	CcSEcCtD
Bosutinib—Vomiting—Vinblastine—kidney cancer	1.97e-05	0.000489	CcSEcCtD
Bosutinib—Dizziness—Erlotinib—kidney cancer	1.97e-05	0.000488	CcSEcCtD
Bosutinib—Ill-defined disorder—Paclitaxel—kidney cancer	1.97e-05	0.000488	CcSEcCtD
Bosutinib—Connective tissue disorder—Capecitabine—kidney cancer	1.97e-05	0.000487	CcSEcCtD
Bosutinib—Vomiting—Everolimus—kidney cancer	1.97e-05	0.000487	CcSEcCtD
Bosutinib—Anaemia—Paclitaxel—kidney cancer	1.96e-05	0.000486	CcSEcCtD
Bosutinib—Urethral disorder—Capecitabine—kidney cancer	1.96e-05	0.000486	CcSEcCtD
Bosutinib—Renal impairment—Doxorubicin—kidney cancer	1.96e-05	0.000486	CcSEcCtD
Bosutinib—Rash—Everolimus—kidney cancer	1.95e-05	0.000483	CcSEcCtD
Bosutinib—Dermatitis—Everolimus—kidney cancer	1.95e-05	0.000482	CcSEcCtD
Bosutinib—Headache—Vinblastine—kidney cancer	1.94e-05	0.000481	CcSEcCtD
Bosutinib—Headache—Everolimus—kidney cancer	1.94e-05	0.000479	CcSEcCtD
Bosutinib—Body temperature increased—Dactinomycin—kidney cancer	1.93e-05	0.000478	CcSEcCtD
Bosutinib—Abdominal pain—Dactinomycin—kidney cancer	1.93e-05	0.000478	CcSEcCtD
Bosutinib—Asthenia—Sorafenib—kidney cancer	1.93e-05	0.000477	CcSEcCtD
Bosutinib—CHEK2—Vinblastine—Vincristine—kidney cancer	1.92e-05	0.0219	CbGdCrCtD
Bosutinib—Malaise—Paclitaxel—kidney cancer	1.92e-05	0.000475	CcSEcCtD
Bosutinib—Leukopenia—Paclitaxel—kidney cancer	1.9e-05	0.000471	CcSEcCtD
Bosutinib—Decreased appetite—Vincristine—kidney cancer	1.9e-05	0.00047	CcSEcCtD
Bosutinib—Pruritus—Sorafenib—kidney cancer	1.9e-05	0.00047	CcSEcCtD
Bosutinib—Vomiting—Erlotinib—kidney cancer	1.9e-05	0.00047	CcSEcCtD
Bosutinib—Erythema multiforme—Capecitabine—kidney cancer	1.89e-05	0.000469	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Gemcitabine—kidney cancer	1.89e-05	0.000467	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Vincristine—kidney cancer	1.89e-05	0.000467	CcSEcCtD
Bosutinib—Fatigue—Vincristine—kidney cancer	1.88e-05	0.000466	CcSEcCtD
Bosutinib—Rash—Erlotinib—kidney cancer	1.88e-05	0.000466	CcSEcCtD
Bosutinib—Dermatitis—Erlotinib—kidney cancer	1.88e-05	0.000465	CcSEcCtD
Bosutinib—Headache—Erlotinib—kidney cancer	1.87e-05	0.000463	CcSEcCtD
Bosutinib—Tinnitus—Capecitabine—kidney cancer	1.87e-05	0.000463	CcSEcCtD
Bosutinib—Pain—Vincristine—kidney cancer	1.87e-05	0.000462	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Doxorubicin—kidney cancer	1.87e-05	0.000462	CcSEcCtD
Bosutinib—Cardiac disorder—Capecitabine—kidney cancer	1.86e-05	0.00046	CcSEcCtD
Bosutinib—Cough—Paclitaxel—kidney cancer	1.85e-05	0.000459	CcSEcCtD
Bosutinib—Asthenia—Sunitinib—kidney cancer	1.85e-05	0.000459	CcSEcCtD
Bosutinib—Dyspnoea—Gemcitabine—kidney cancer	1.85e-05	0.000457	CcSEcCtD
Bosutinib—Nausea—Vinblastine—kidney cancer	1.84e-05	0.000456	CcSEcCtD
Bosutinib—CSK—Daunorubicin—Doxorubicin—kidney cancer	1.84e-05	0.021	CbGdCrCtD
Bosutinib—CSK—Epirubicin—Doxorubicin—kidney cancer	1.84e-05	0.021	CbGdCrCtD
Bosutinib—Nausea—Everolimus—kidney cancer	1.84e-05	0.000455	CcSEcCtD
Bosutinib—Diarrhoea—Sorafenib—kidney cancer	1.84e-05	0.000455	CcSEcCtD
Bosutinib—Pruritus—Sunitinib—kidney cancer	1.83e-05	0.000452	CcSEcCtD
Bosutinib—Immune system disorder—Capecitabine—kidney cancer	1.81e-05	0.000448	CcSEcCtD
Bosutinib—Myalgia—Paclitaxel—kidney cancer	1.81e-05	0.000448	CcSEcCtD
Bosutinib—Chest pain—Paclitaxel—kidney cancer	1.81e-05	0.000448	CcSEcCtD
Bosutinib—Arthralgia—Paclitaxel—kidney cancer	1.81e-05	0.000448	CcSEcCtD
Bosutinib—Mediastinal disorder—Capecitabine—kidney cancer	1.81e-05	0.000447	CcSEcCtD
Bosutinib—Face oedema—Doxorubicin—kidney cancer	1.8e-05	0.000446	CcSEcCtD
Bosutinib—Decreased appetite—Gemcitabine—kidney cancer	1.8e-05	0.000446	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	1.8e-05	0.000445	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Gemcitabine—kidney cancer	1.79e-05	0.000443	CcSEcCtD
Bosutinib—Discomfort—Paclitaxel—kidney cancer	1.79e-05	0.000443	CcSEcCtD
Bosutinib—Fatigue—Gemcitabine—kidney cancer	1.79e-05	0.000442	CcSEcCtD
Bosutinib—Gastrointestinal pain—Vincristine—kidney cancer	1.79e-05	0.000442	CcSEcCtD
Bosutinib—Dizziness—Sorafenib—kidney cancer	1.77e-05	0.000439	CcSEcCtD
Bosutinib—Pain—Gemcitabine—kidney cancer	1.77e-05	0.000439	CcSEcCtD
Bosutinib—Nausea—Erlotinib—kidney cancer	1.77e-05	0.000439	CcSEcCtD
Bosutinib—Diarrhoea—Sunitinib—kidney cancer	1.77e-05	0.000437	CcSEcCtD
Bosutinib—Asthenia—Dactinomycin—kidney cancer	1.75e-05	0.000434	CcSEcCtD
Bosutinib—Blood creatinine increased—Doxorubicin—kidney cancer	1.75e-05	0.000433	CcSEcCtD
Bosutinib—Malnutrition—Capecitabine—kidney cancer	1.74e-05	0.000432	CcSEcCtD
Bosutinib—Dehydration—Doxorubicin—kidney cancer	1.74e-05	0.00043	CcSEcCtD
Bosutinib—Oedema—Paclitaxel—kidney cancer	1.73e-05	0.000429	CcSEcCtD
Bosutinib—Anaphylactic shock—Paclitaxel—kidney cancer	1.73e-05	0.000429	CcSEcCtD
Bosutinib—Body temperature increased—Vincristine—kidney cancer	1.73e-05	0.000427	CcSEcCtD
Bosutinib—Abdominal pain—Vincristine—kidney cancer	1.73e-05	0.000427	CcSEcCtD
Bosutinib—Infection—Paclitaxel—kidney cancer	1.72e-05	0.000427	CcSEcCtD
Bosutinib—Dysgeusia—Capecitabine—kidney cancer	1.71e-05	0.000423	CcSEcCtD
Bosutinib—Dizziness—Sunitinib—kidney cancer	1.71e-05	0.000423	CcSEcCtD
Bosutinib—Feeling abnormal—Gemcitabine—kidney cancer	1.71e-05	0.000423	CcSEcCtD
Bosutinib—Vomiting—Sorafenib—kidney cancer	1.71e-05	0.000422	CcSEcCtD
Bosutinib—Abdominal pain upper—Doxorubicin—kidney cancer	1.71e-05	0.000422	CcSEcCtD
Bosutinib—Nervous system disorder—Paclitaxel—kidney cancer	1.7e-05	0.000421	CcSEcCtD
Bosutinib—Thrombocytopenia—Paclitaxel—kidney cancer	1.7e-05	0.00042	CcSEcCtD
Bosutinib—Rash—Sorafenib—kidney cancer	1.69e-05	0.000419	CcSEcCtD
Bosutinib—Dermatitis—Sorafenib—kidney cancer	1.69e-05	0.000419	CcSEcCtD
Bosutinib—Back pain—Capecitabine—kidney cancer	1.69e-05	0.000418	CcSEcCtD
Bosutinib—Skin disorder—Paclitaxel—kidney cancer	1.68e-05	0.000417	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	1.68e-05	0.000416	CcSEcCtD
Bosutinib—Headache—Sorafenib—kidney cancer	1.68e-05	0.000416	CcSEcCtD
Bosutinib—Diarrhoea—Dactinomycin—kidney cancer	1.67e-05	0.000414	CcSEcCtD
Bosutinib—Nasopharyngitis—Doxorubicin—kidney cancer	1.67e-05	0.000413	CcSEcCtD
Bosutinib—ABCB1—nephron tubule—kidney cancer	1.66e-05	0.000679	CbGeAlD
Bosutinib—Gastritis—Doxorubicin—kidney cancer	1.65e-05	0.000409	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Doxorubicin—kidney cancer	1.65e-05	0.000408	CcSEcCtD
Bosutinib—Vomiting—Sunitinib—kidney cancer	1.64e-05	0.000406	CcSEcCtD
Bosutinib—Body temperature increased—Gemcitabine—kidney cancer	1.64e-05	0.000405	CcSEcCtD
Bosutinib—Rash—Sunitinib—kidney cancer	1.63e-05	0.000403	CcSEcCtD
Bosutinib—Dermatitis—Sunitinib—kidney cancer	1.63e-05	0.000403	CcSEcCtD
Bosutinib—Ill-defined disorder—Capecitabine—kidney cancer	1.62e-05	0.000401	CcSEcCtD
Bosutinib—Headache—Sunitinib—kidney cancer	1.62e-05	0.0004	CcSEcCtD
Bosutinib—Influenza—Doxorubicin—kidney cancer	1.61e-05	0.000399	CcSEcCtD
Bosutinib—Anaemia—Capecitabine—kidney cancer	1.61e-05	0.000399	CcSEcCtD
Bosutinib—Nausea—Sorafenib—kidney cancer	1.59e-05	0.000395	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Paclitaxel—kidney cancer	1.58e-05	0.000391	CcSEcCtD
Bosutinib—Malaise—Capecitabine—kidney cancer	1.57e-05	0.000389	CcSEcCtD
Bosutinib—Asthenia—Vincristine—kidney cancer	1.57e-05	0.000388	CcSEcCtD
Bosutinib—Leukopenia—Capecitabine—kidney cancer	1.56e-05	0.000387	CcSEcCtD
Bosutinib—Vomiting—Dactinomycin—kidney cancer	1.55e-05	0.000385	CcSEcCtD
Bosutinib—Bronchitis—Doxorubicin—kidney cancer	1.55e-05	0.000384	CcSEcCtD
Bosutinib—Dyspnoea—Paclitaxel—kidney cancer	1.55e-05	0.000383	CcSEcCtD
Bosutinib—Rash—Dactinomycin—kidney cancer	1.54e-05	0.000382	CcSEcCtD
Bosutinib—Nausea—Sunitinib—kidney cancer	1.53e-05	0.00038	CcSEcCtD
Bosutinib—Pancytopenia—Doxorubicin—kidney cancer	1.53e-05	0.000379	CcSEcCtD
Bosutinib—Cough—Capecitabine—kidney cancer	1.52e-05	0.000377	CcSEcCtD
Bosutinib—ABCB1—renal system—kidney cancer	1.51e-05	0.000617	CbGeAlD
Bosutinib—Neutropenia—Doxorubicin—kidney cancer	1.51e-05	0.000374	CcSEcCtD
Bosutinib—Decreased appetite—Paclitaxel—kidney cancer	1.51e-05	0.000373	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Doxorubicin—kidney cancer	1.5e-05	0.000371	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Paclitaxel—kidney cancer	1.5e-05	0.000371	CcSEcCtD
Bosutinib—Fatigue—Paclitaxel—kidney cancer	1.5e-05	0.00037	CcSEcCtD
Bosutinib—Diarrhoea—Vincristine—kidney cancer	1.49e-05	0.00037	CcSEcCtD
Bosutinib—Asthenia—Gemcitabine—kidney cancer	1.49e-05	0.000368	CcSEcCtD
Bosutinib—Chest pain—Capecitabine—kidney cancer	1.48e-05	0.000368	CcSEcCtD
Bosutinib—Myalgia—Capecitabine—kidney cancer	1.48e-05	0.000368	CcSEcCtD
Bosutinib—Arthralgia—Capecitabine—kidney cancer	1.48e-05	0.000368	CcSEcCtD
Bosutinib—Pain—Paclitaxel—kidney cancer	1.48e-05	0.000367	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	1.47e-05	0.000365	CcSEcCtD
Bosutinib—Discomfort—Capecitabine—kidney cancer	1.47e-05	0.000363	CcSEcCtD
Bosutinib—Pruritus—Gemcitabine—kidney cancer	1.47e-05	0.000363	CcSEcCtD
Bosutinib—ABCB1—kidney—kidney cancer	1.46e-05	0.000597	CbGeAlD
Bosutinib—Nausea—Dactinomycin—kidney cancer	1.45e-05	0.000359	CcSEcCtD
Bosutinib—Pneumonia—Doxorubicin—kidney cancer	1.45e-05	0.000358	CcSEcCtD
Bosutinib—Dizziness—Vincristine—kidney cancer	1.44e-05	0.000358	CcSEcCtD
Bosutinib—Infestation—Doxorubicin—kidney cancer	1.44e-05	0.000356	CcSEcCtD
Bosutinib—Infestation NOS—Doxorubicin—kidney cancer	1.44e-05	0.000356	CcSEcCtD
Bosutinib—Feeling abnormal—Paclitaxel—kidney cancer	1.43e-05	0.000354	CcSEcCtD
Bosutinib—ABCB1—cortex of kidney—kidney cancer	1.42e-05	0.000581	CbGeAlD
Bosutinib—Oedema—Capecitabine—kidney cancer	1.42e-05	0.000352	CcSEcCtD
Bosutinib—Gastrointestinal pain—Paclitaxel—kidney cancer	1.42e-05	0.000351	CcSEcCtD
Bosutinib—Diarrhoea—Gemcitabine—kidney cancer	1.42e-05	0.000351	CcSEcCtD
Bosutinib—Renal failure—Doxorubicin—kidney cancer	1.41e-05	0.00035	CcSEcCtD
Bosutinib—Infection—Capecitabine—kidney cancer	1.41e-05	0.00035	CcSEcCtD
Bosutinib—Nervous system disorder—Capecitabine—kidney cancer	1.4e-05	0.000346	CcSEcCtD
Bosutinib—Thrombocytopenia—Capecitabine—kidney cancer	1.39e-05	0.000345	CcSEcCtD
Bosutinib—Vomiting—Vincristine—kidney cancer	1.39e-05	0.000344	CcSEcCtD
Bosutinib—Skin disorder—Capecitabine—kidney cancer	1.38e-05	0.000342	CcSEcCtD
Bosutinib—Urticaria—Paclitaxel—kidney cancer	1.38e-05	0.000341	CcSEcCtD
Bosutinib—Rash—Vincristine—kidney cancer	1.38e-05	0.000341	CcSEcCtD
Bosutinib—Dermatitis—Vincristine—kidney cancer	1.38e-05	0.000341	CcSEcCtD
Bosutinib—Abdominal pain—Paclitaxel—kidney cancer	1.37e-05	0.000339	CcSEcCtD
Bosutinib—Body temperature increased—Paclitaxel—kidney cancer	1.37e-05	0.000339	CcSEcCtD
Bosutinib—Headache—Vincristine—kidney cancer	1.37e-05	0.000339	CcSEcCtD
Bosutinib—Hepatobiliary disease—Doxorubicin—kidney cancer	1.36e-05	0.000337	CcSEcCtD
Bosutinib—ABCB1—gonad—kidney cancer	1.36e-05	0.000554	CbGeAlD
Bosutinib—CHEK2—Epirubicin—Doxorubicin—kidney cancer	1.35e-05	0.0153	CbGdCrCtD
Bosutinib—Agranulocytosis—Doxorubicin—kidney cancer	1.34e-05	0.000332	CcSEcCtD
Bosutinib—Vomiting—Gemcitabine—kidney cancer	1.32e-05	0.000326	CcSEcCtD
Bosutinib—Rash—Gemcitabine—kidney cancer	1.31e-05	0.000323	CcSEcCtD
Bosutinib—Dermatitis—Gemcitabine—kidney cancer	1.31e-05	0.000323	CcSEcCtD
Bosutinib—Headache—Gemcitabine—kidney cancer	1.3e-05	0.000321	CcSEcCtD
Bosutinib—Nausea—Vincristine—kidney cancer	1.3e-05	0.000321	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Capecitabine—kidney cancer	1.3e-05	0.000321	CcSEcCtD
Bosutinib—Hepatitis—Doxorubicin—kidney cancer	1.29e-05	0.00032	CcSEcCtD
Bosutinib—ABL1—Idarubicin—Doxorubicin—kidney cancer	1.29e-05	0.0146	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Doxorubicin—kidney cancer	1.29e-05	0.0146	CbGdCrCtD
Bosutinib—ABL1—Epirubicin—Doxorubicin—kidney cancer	1.29e-05	0.0146	CbGdCrCtD
Bosutinib—Urinary tract disorder—Doxorubicin—kidney cancer	1.28e-05	0.000316	CcSEcCtD
Bosutinib—Oedema peripheral—Doxorubicin—kidney cancer	1.27e-05	0.000315	CcSEcCtD
Bosutinib—Connective tissue disorder—Doxorubicin—kidney cancer	1.27e-05	0.000314	CcSEcCtD
Bosutinib—Dyspnoea—Capecitabine—kidney cancer	1.27e-05	0.000314	CcSEcCtD
Bosutinib—Urethral disorder—Doxorubicin—kidney cancer	1.27e-05	0.000313	CcSEcCtD
Bosutinib—Asthenia—Paclitaxel—kidney cancer	1.24e-05	0.000308	CcSEcCtD
Bosutinib—Decreased appetite—Capecitabine—kidney cancer	1.24e-05	0.000306	CcSEcCtD
Bosutinib—Nausea—Gemcitabine—kidney cancer	1.23e-05	0.000305	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Capecitabine—kidney cancer	1.23e-05	0.000304	CcSEcCtD
Bosutinib—Fatigue—Capecitabine—kidney cancer	1.23e-05	0.000304	CcSEcCtD
Bosutinib—Pruritus—Paclitaxel—kidney cancer	1.23e-05	0.000304	CcSEcCtD
Bosutinib—Erythema multiforme—Doxorubicin—kidney cancer	1.22e-05	0.000302	CcSEcCtD
Bosutinib—Pain—Capecitabine—kidney cancer	1.22e-05	0.000301	CcSEcCtD
Bosutinib—Tinnitus—Doxorubicin—kidney cancer	1.2e-05	0.000298	CcSEcCtD
Bosutinib—Cardiac disorder—Doxorubicin—kidney cancer	1.2e-05	0.000297	CcSEcCtD
Bosutinib—Diarrhoea—Paclitaxel—kidney cancer	1.19e-05	0.000294	CcSEcCtD
Bosutinib—Feeling abnormal—Capecitabine—kidney cancer	1.17e-05	0.00029	CcSEcCtD
Bosutinib—Immune system disorder—Doxorubicin—kidney cancer	1.17e-05	0.000289	CcSEcCtD
Bosutinib—Gastrointestinal pain—Capecitabine—kidney cancer	1.16e-05	0.000288	CcSEcCtD
Bosutinib—Mediastinal disorder—Doxorubicin—kidney cancer	1.16e-05	0.000288	CcSEcCtD
Bosutinib—Dizziness—Paclitaxel—kidney cancer	1.15e-05	0.000284	CcSEcCtD
Bosutinib—Urticaria—Capecitabine—kidney cancer	1.13e-05	0.00028	CcSEcCtD
Bosutinib—Abdominal pain—Capecitabine—kidney cancer	1.13e-05	0.000279	CcSEcCtD
Bosutinib—Body temperature increased—Capecitabine—kidney cancer	1.13e-05	0.000279	CcSEcCtD
Bosutinib—Malnutrition—Doxorubicin—kidney cancer	1.12e-05	0.000278	CcSEcCtD
Bosutinib—Vomiting—Paclitaxel—kidney cancer	1.1e-05	0.000273	CcSEcCtD
Bosutinib—Dysgeusia—Doxorubicin—kidney cancer	1.1e-05	0.000273	CcSEcCtD
Bosutinib—Rash—Paclitaxel—kidney cancer	1.09e-05	0.000271	CcSEcCtD
Bosutinib—Dermatitis—Paclitaxel—kidney cancer	1.09e-05	0.000271	CcSEcCtD
Bosutinib—Back pain—Doxorubicin—kidney cancer	1.09e-05	0.000269	CcSEcCtD
Bosutinib—Headache—Paclitaxel—kidney cancer	1.09e-05	0.000269	CcSEcCtD
Bosutinib—Ill-defined disorder—Doxorubicin—kidney cancer	1.04e-05	0.000258	CcSEcCtD
Bosutinib—Anaemia—Doxorubicin—kidney cancer	1.04e-05	0.000257	CcSEcCtD
Bosutinib—Nausea—Paclitaxel—kidney cancer	1.03e-05	0.000255	CcSEcCtD
Bosutinib—Asthenia—Capecitabine—kidney cancer	1.02e-05	0.000253	CcSEcCtD
Bosutinib—Malaise—Doxorubicin—kidney cancer	1.01e-05	0.000251	CcSEcCtD
Bosutinib—Pruritus—Capecitabine—kidney cancer	1.01e-05	0.000249	CcSEcCtD
Bosutinib—Leukopenia—Doxorubicin—kidney cancer	1.01e-05	0.000249	CcSEcCtD
Bosutinib—Cough—Doxorubicin—kidney cancer	9.81e-06	0.000243	CcSEcCtD
Bosutinib—Diarrhoea—Capecitabine—kidney cancer	9.74e-06	0.000241	CcSEcCtD
Bosutinib—Arthralgia—Doxorubicin—kidney cancer	9.57e-06	0.000237	CcSEcCtD
Bosutinib—Chest pain—Doxorubicin—kidney cancer	9.57e-06	0.000237	CcSEcCtD
Bosutinib—Myalgia—Doxorubicin—kidney cancer	9.57e-06	0.000237	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	9.51e-06	0.000235	CcSEcCtD
Bosutinib—Discomfort—Doxorubicin—kidney cancer	9.46e-06	0.000234	CcSEcCtD
Bosutinib—Dizziness—Capecitabine—kidney cancer	9.41e-06	0.000233	CcSEcCtD
Bosutinib—Anaphylactic shock—Doxorubicin—kidney cancer	9.18e-06	0.000227	CcSEcCtD
Bosutinib—Oedema—Doxorubicin—kidney cancer	9.18e-06	0.000227	CcSEcCtD
Bosutinib—Infection—Doxorubicin—kidney cancer	9.12e-06	0.000226	CcSEcCtD
Bosutinib—Vomiting—Capecitabine—kidney cancer	9.05e-06	0.000224	CcSEcCtD
Bosutinib—Nervous system disorder—Doxorubicin—kidney cancer	9e-06	0.000223	CcSEcCtD
Bosutinib—Thrombocytopenia—Doxorubicin—kidney cancer	8.98e-06	0.000222	CcSEcCtD
Bosutinib—Rash—Capecitabine—kidney cancer	8.97e-06	0.000222	CcSEcCtD
Bosutinib—Dermatitis—Capecitabine—kidney cancer	8.97e-06	0.000222	CcSEcCtD
Bosutinib—Headache—Capecitabine—kidney cancer	8.92e-06	0.000221	CcSEcCtD
Bosutinib—Skin disorder—Doxorubicin—kidney cancer	8.91e-06	0.000221	CcSEcCtD
Bosutinib—Nausea—Capecitabine—kidney cancer	8.45e-06	0.000209	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Doxorubicin—kidney cancer	8.36e-06	0.000207	CcSEcCtD
Bosutinib—Dyspnoea—Doxorubicin—kidney cancer	8.18e-06	0.000203	CcSEcCtD
Bosutinib—Decreased appetite—Doxorubicin—kidney cancer	7.98e-06	0.000197	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Doxorubicin—kidney cancer	7.92e-06	0.000196	CcSEcCtD
Bosutinib—Fatigue—Doxorubicin—kidney cancer	7.91e-06	0.000196	CcSEcCtD
Bosutinib—Pain—Doxorubicin—kidney cancer	7.85e-06	0.000194	CcSEcCtD
Bosutinib—Feeling abnormal—Doxorubicin—kidney cancer	7.56e-06	0.000187	CcSEcCtD
Bosutinib—Gastrointestinal pain—Doxorubicin—kidney cancer	7.5e-06	0.000186	CcSEcCtD
Bosutinib—Urticaria—Doxorubicin—kidney cancer	7.29e-06	0.00018	CcSEcCtD
Bosutinib—Body temperature increased—Doxorubicin—kidney cancer	7.25e-06	0.00018	CcSEcCtD
Bosutinib—Abdominal pain—Doxorubicin—kidney cancer	7.25e-06	0.00018	CcSEcCtD
Bosutinib—Asthenia—Doxorubicin—kidney cancer	6.58e-06	0.000163	CcSEcCtD
Bosutinib—Pruritus—Doxorubicin—kidney cancer	6.49e-06	0.000161	CcSEcCtD
Bosutinib—Diarrhoea—Doxorubicin—kidney cancer	6.28e-06	0.000155	CcSEcCtD
Bosutinib—Dizziness—Doxorubicin—kidney cancer	6.07e-06	0.00015	CcSEcCtD
Bosutinib—Vomiting—Doxorubicin—kidney cancer	5.83e-06	0.000144	CcSEcCtD
Bosutinib—Rash—Doxorubicin—kidney cancer	5.79e-06	0.000143	CcSEcCtD
Bosutinib—Dermatitis—Doxorubicin—kidney cancer	5.78e-06	0.000143	CcSEcCtD
Bosutinib—Headache—Doxorubicin—kidney cancer	5.75e-06	0.000142	CcSEcCtD
Bosutinib—Nausea—Doxorubicin—kidney cancer	5.45e-06	0.000135	CcSEcCtD
Bosutinib—LCK—Signaling Pathways—POMC—kidney cancer	1.44e-07	2.99e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—KRAS—kidney cancer	1.43e-07	2.97e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—ERBB2—kidney cancer	1.43e-07	2.97e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—MAPK1—kidney cancer	1.43e-07	2.97e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—PTEN—kidney cancer	1.43e-07	2.97e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—PIK3CA—kidney cancer	1.43e-07	2.96e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—KRAS—kidney cancer	1.43e-07	2.96e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—MYC—kidney cancer	1.43e-07	2.96e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—RAF1—kidney cancer	1.43e-07	2.96e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TP53—kidney cancer	1.42e-07	2.95e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—BRAF—kidney cancer	1.42e-07	2.95e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—KRAS—kidney cancer	1.42e-07	2.95e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—MYC—kidney cancer	1.42e-07	2.94e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MAPK3—kidney cancer	1.42e-07	2.94e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—RELA—kidney cancer	1.42e-07	2.94e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—RAF1—kidney cancer	1.42e-07	2.94e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—PIK3CA—kidney cancer	1.42e-07	2.94e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—JUN—kidney cancer	1.42e-07	2.94e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MTOR—kidney cancer	1.41e-07	2.93e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—RELA—kidney cancer	1.41e-07	2.93e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—ERBB2—kidney cancer	1.41e-07	2.93e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—CTNNB1—kidney cancer	1.41e-07	2.92e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—VEGFA—kidney cancer	1.4e-07	2.91e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—ERBB2—kidney cancer	1.4e-07	2.91e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—KRAS—kidney cancer	1.4e-07	2.91e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MAPK3—kidney cancer	1.4e-07	2.9e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—MAPK1—kidney cancer	1.4e-07	2.9e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—PIK3CA—kidney cancer	1.4e-07	2.89e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MTOR—kidney cancer	1.39e-07	2.89e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—MAPK1—kidney cancer	1.39e-07	2.88e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CDKN1B—kidney cancer	1.39e-07	2.88e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GSTP1—kidney cancer	1.39e-07	2.88e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MTOR—kidney cancer	1.38e-07	2.87e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MYC—kidney cancer	1.38e-07	2.86e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—CDKN1B—kidney cancer	1.38e-07	2.85e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—MAPK3—kidney cancer	1.37e-07	2.85e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TP53—kidney cancer	1.37e-07	2.84e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—PTEN—kidney cancer	1.37e-07	2.84e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—KRAS—kidney cancer	1.37e-07	2.84e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—PIK3CA—kidney cancer	1.37e-07	2.83e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—PIK3CA—kidney cancer	1.37e-07	2.83e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MYC—kidney cancer	1.36e-07	2.82e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—PIK3CA—kidney cancer	1.36e-07	2.82e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL2—kidney cancer	1.36e-07	2.82e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CDKN1B—kidney cancer	1.36e-07	2.81e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ITPR2—kidney cancer	1.35e-07	2.81e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—KRAS—kidney cancer	1.35e-07	2.8e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MAPK1—kidney cancer	1.35e-07	2.8e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KIT—kidney cancer	1.34e-07	2.78e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—APC—kidney cancer	1.34e-07	2.78e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—PIK3CA—kidney cancer	1.33e-07	2.76e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MAPK1—kidney cancer	1.33e-07	2.76e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MAPK3—kidney cancer	1.33e-07	2.75e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—PIK3CA—kidney cancer	1.33e-07	2.75e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CDKN1B—kidney cancer	1.33e-07	2.75e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL2—kidney cancer	1.33e-07	2.75e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CCND1—kidney cancer	1.32e-07	2.75e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—MAPK3—kidney cancer	1.32e-07	2.74e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—JUN—kidney cancer	1.32e-07	2.74e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—VEGFA—kidney cancer	1.32e-07	2.74e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TP53—kidney cancer	1.32e-07	2.74e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TP53—kidney cancer	1.32e-07	2.74e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—KRAS—kidney cancer	1.32e-07	2.74e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—PIK3CA—kidney cancer	1.32e-07	2.73e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—PIK3CA—kidney cancer	1.31e-07	2.72e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CTNNB1—kidney cancer	1.31e-07	2.72e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—KRAS—kidney cancer	1.31e-07	2.72e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—MAPK1—kidney cancer	1.31e-07	2.71e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CDKN1B—kidney cancer	1.31e-07	2.71e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—PIK3CA—kidney cancer	1.31e-07	2.71e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CDKN1B—kidney cancer	1.3e-07	2.69e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—CTNNB1—kidney cancer	1.3e-07	2.69e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL2—kidney cancer	1.3e-07	2.69e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CCND1—kidney cancer	1.29e-07	2.68e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MYC—kidney cancer	1.29e-07	2.68e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—JUN—kidney cancer	1.29e-07	2.68e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—PIK3CA—kidney cancer	1.29e-07	2.67e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CTNNB1—kidney cancer	1.28e-07	2.66e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PTEN—kidney cancer	1.28e-07	2.65e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL2—kidney cancer	1.28e-07	2.65e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GSTM1—kidney cancer	1.28e-07	2.65e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—KRAS—kidney cancer	1.28e-07	2.65e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—POMC—kidney cancer	1.27e-07	2.64e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—kidney cancer	1.27e-07	2.64e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL2—kidney cancer	1.27e-07	2.64e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—MAPK3—kidney cancer	1.27e-07	2.63e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PTEN—kidney cancer	1.27e-07	2.63e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CCND1—kidney cancer	1.27e-07	2.63e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MAPK1—kidney cancer	1.26e-07	2.62e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—JUN—kidney cancer	1.26e-07	2.62e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—MAPK1—kidney cancer	1.26e-07	2.61e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—BRAF—kidney cancer	1.26e-07	2.61e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—KRAS—kidney cancer	1.26e-07	2.61e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—PIK3CA—kidney cancer	1.26e-07	2.61e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CTNNB1—kidney cancer	1.25e-07	2.6e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MAPK3—kidney cancer	1.25e-07	2.59e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PTEN—kidney cancer	1.25e-07	2.59e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CCND1—kidney cancer	1.25e-07	2.58e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—JUN—kidney cancer	1.24e-07	2.58e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—PIK3CA—kidney cancer	1.24e-07	2.57e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CCND1—kidney cancer	1.24e-07	2.57e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—JUN—kidney cancer	1.24e-07	2.57e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—KRAS—kidney cancer	1.23e-07	2.56e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CTNNB1—kidney cancer	1.23e-07	2.56e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ACHE—kidney cancer	1.23e-07	2.56e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTT1—kidney cancer	1.23e-07	2.56e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—MYC—kidney cancer	1.23e-07	2.56e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—RAF1—kidney cancer	1.23e-07	2.55e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CTNNB1—kidney cancer	1.23e-07	2.55e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—RELA—kidney cancer	1.23e-07	2.54e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MAPK3—kidney cancer	1.22e-07	2.53e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PTEN—kidney cancer	1.22e-07	2.53e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—ERBB2—kidney cancer	1.22e-07	2.53e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MYC—kidney cancer	1.22e-07	2.52e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—PIK3CA—kidney cancer	1.21e-07	2.51e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CYP1A1—kidney cancer	1.21e-07	2.51e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—MAPK1—kidney cancer	1.21e-07	2.5e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—PIK3CA—kidney cancer	1.21e-07	2.5e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PTEN—kidney cancer	1.2e-07	2.49e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MTOR—kidney cancer	1.2e-07	2.49e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PTEN—kidney cancer	1.2e-07	2.48e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—KRAS—kidney cancer	1.19e-07	2.47e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MAPK1—kidney cancer	1.19e-07	2.47e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—KRAS—kidney cancer	1.19e-07	2.47e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MYC—kidney cancer	1.19e-07	2.46e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—RAF1—kidney cancer	1.19e-07	2.46e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—RELA—kidney cancer	1.18e-07	2.45e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—ERBB2—kidney cancer	1.17e-07	2.44e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—PIK3CA—kidney cancer	1.17e-07	2.43e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—MAPK3—kidney cancer	1.17e-07	2.43e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SCARB1—kidney cancer	1.17e-07	2.42e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MAPK1—kidney cancer	1.16e-07	2.41e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MTOR—kidney cancer	1.16e-07	2.4e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS1—kidney cancer	1.16e-07	2.4e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—PIK3CA—kidney cancer	1.16e-07	2.4e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—VEGFA—kidney cancer	1.16e-07	2.4e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—KRAS—kidney cancer	1.14e-07	2.36e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PSMD7—kidney cancer	1.13e-07	2.35e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—kidney cancer	1.13e-07	2.35e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—PIK3CA—kidney cancer	1.13e-07	2.35e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CDKN1B—kidney cancer	1.13e-07	2.34e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VEGFA—kidney cancer	1.13e-07	2.34e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KRAS—kidney cancer	1.12e-07	2.33e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—kidney cancer	1.12e-07	2.32e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—MAPK1—kidney cancer	1.11e-07	2.31e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL2—kidney cancer	1.1e-07	2.29e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VEGFA—kidney cancer	1.1e-07	2.29e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—KRAS—kidney cancer	1.1e-07	2.28e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—PIK3CA—kidney cancer	1.1e-07	2.27e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—PIK3CA—kidney cancer	1.09e-07	2.27e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MAPK3—kidney cancer	1.09e-07	2.27e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CDKN1B—kidney cancer	1.09e-07	2.26e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VEGFA—kidney cancer	1.09e-07	2.25e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MAPK3—kidney cancer	1.08e-07	2.24e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VEGFA—kidney cancer	1.08e-07	2.24e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCND1—kidney cancer	1.08e-07	2.23e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—BCHE—kidney cancer	1.08e-07	2.23e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—JUN—kidney cancer	1.07e-07	2.23e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MAPK3—kidney cancer	1.07e-07	2.21e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CTNNB1—kidney cancer	1.07e-07	2.21e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL2—kidney cancer	1.06e-07	2.21e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MYC—kidney cancer	1.06e-07	2.2e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC5A5—kidney cancer	1.06e-07	2.2e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—kidney cancer	1.06e-07	2.2e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—KRAS—kidney cancer	1.05e-07	2.18e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MYC—kidney cancer	1.05e-07	2.18e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—RAF1—kidney cancer	1.05e-07	2.18e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—PIK3CA—kidney cancer	1.05e-07	2.17e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—RELA—kidney cancer	1.05e-07	2.17e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MAPK3—kidney cancer	1.04e-07	2.17e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ERBB2—kidney cancer	1.04e-07	2.16e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MAPK1—kidney cancer	1.04e-07	2.16e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PTEN—kidney cancer	1.04e-07	2.16e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCND1—kidney cancer	1.04e-07	2.15e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MYC—kidney cancer	1.04e-07	2.15e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—JUN—kidney cancer	1.04e-07	2.15e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PIK3CA—kidney cancer	1.03e-07	2.14e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MAPK1—kidney cancer	1.03e-07	2.13e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MAPK3—kidney cancer	1.03e-07	2.13e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CTNNB1—kidney cancer	1.03e-07	2.13e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MTOR—kidney cancer	1.03e-07	2.13e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC2A1—kidney cancer	1.03e-07	2.13e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MAPK3—kidney cancer	1.02e-07	2.12e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MYC—kidney cancer	1.02e-07	2.11e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MAPK1—kidney cancer	1.01e-07	2.1e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—PIK3CA—kidney cancer	1.01e-07	2.09e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PTEN—kidney cancer	1e-07	2.08e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MYC—kidney cancer	1e-07	2.07e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—kidney cancer	9.99e-08	2.07e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MYC—kidney cancer	9.94e-08	2.06e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MAPK1—kidney cancer	9.93e-08	2.06e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KRAS—kidney cancer	9.82e-08	2.04e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MAPK1—kidney cancer	9.78e-08	2.03e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MAPK1—kidney cancer	9.73e-08	2.02e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—KRAS—kidney cancer	9.72e-08	2.02e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—PIK3CA—kidney cancer	9.67e-08	2.01e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CDKN1B—kidney cancer	9.63e-08	2e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KRAS—kidney cancer	9.58e-08	1.99e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL2—kidney cancer	9.42e-08	1.95e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VEGFA—kidney cancer	9.39e-08	1.95e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KRAS—kidney cancer	9.38e-08	1.95e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KRAS—kidney cancer	9.24e-08	1.92e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KRAS—kidney cancer	9.19e-08	1.91e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCND1—kidney cancer	9.19e-08	1.9e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—JUN—kidney cancer	9.17e-08	1.9e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CTNNB1—kidney cancer	9.1e-08	1.89e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VEGFA—kidney cancer	9.05e-08	1.88e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PIK3CA—kidney cancer	9.02e-08	1.87e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—POMC—kidney cancer	9.02e-08	1.87e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PIK3CA—kidney cancer	8.93e-08	1.85e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MAPK3—kidney cancer	8.88e-08	1.84e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PTEN—kidney cancer	8.87e-08	1.84e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PIK3CA—kidney cancer	8.8e-08	1.83e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—kidney cancer	8.73e-08	1.81e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MYC—kidney cancer	8.64e-08	1.79e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PIK3CA—kidney cancer	8.62e-08	1.79e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MAPK3—kidney cancer	8.56e-08	1.77e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTP1—kidney cancer	8.55e-08	1.77e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—kidney cancer	8.52e-08	1.77e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PIK3CA—kidney cancer	8.49e-08	1.76e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MAPK1—kidney cancer	8.45e-08	1.75e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PIK3CA—kidney cancer	8.44e-08	1.75e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—kidney cancer	8.34e-08	1.73e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MYC—kidney cancer	8.32e-08	1.73e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—kidney cancer	8.21e-08	1.7e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—kidney cancer	8.17e-08	1.69e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MAPK1—kidney cancer	8.14e-08	1.69e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ABCB1—kidney cancer	8.1e-08	1.68e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VEGFA—kidney cancer	8.01e-08	1.66e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KRAS—kidney cancer	7.98e-08	1.65e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTM1—kidney cancer	7.86e-08	1.63e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KRAS—kidney cancer	7.69e-08	1.59e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAPK3—kidney cancer	7.58e-08	1.57e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP1A1—kidney cancer	7.45e-08	1.55e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MYC—kidney cancer	7.37e-08	1.53e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3CA—kidney cancer	7.33e-08	1.52e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAPK1—kidney cancer	7.21e-08	1.49e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—kidney cancer	7.19e-08	1.49e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—kidney cancer	7.09e-08	1.47e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CA—kidney cancer	7.07e-08	1.47e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—kidney cancer	6.83e-08	1.42e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KRAS—kidney cancer	6.81e-08	1.41e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTEN—kidney cancer	6.27e-08	1.3e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CA—kidney cancer	6.25e-08	1.3e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—kidney cancer	6.05e-08	1.25e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—POMC—kidney cancer	5.56e-08	1.15e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—kidney cancer	4.43e-08	9.19e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CA—kidney cancer	4.43e-08	9.18e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTEN—kidney cancer	3.86e-08	8.02e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CA—kidney cancer	2.73e-08	5.65e-07	CbGpPWpGaD
